Repetition of serotonin syndrome after reexposure to SSRI: A case report

Pharmacopsychiatry

Volumn 37, Issue 5, 2004, Pages 236-238

  Tomaselli, G ^a   Modestin, J ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CITALOPRAM; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; OXAZEPAM; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VITAMIN;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG REEXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER METABOLISM; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SEROTONIN SYNDROME;

CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MIDDLE AGED; RECURRENCE; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 4644233693     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832598     Document Type: Article

References (16)

1. Azaz-Livshits T, Hershko A, Ben-Chetrit E. Paroxetin associated hepatotoxicity: a report of 3 cases and a review of the literature. Pharmacopsychiatry 2002; 35: 112-115
2. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31: 444-469
3. Bottlender R, Jäger M, Hofschuster E, Dobmeier P, Möller H-J. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry 2002; 35: 119-121
4. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996; 30: 527-533
5. Démolis J-L, Angebaud P, Grangé J-D, Coates P, Funck-Brentano C, Jaillon P. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol 1996; 42: 394-397
6. Dursun SM, Burke JG, Reveley MA. Toxic serotonin syndrome or extra-pyramidal side-effects. Br J Psychiatry 1995; 166: 401-402
7. Hegerl U, Bottlender R, Gallinat J, Kuss HJ, Ackenheil M, Möller HJ. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci 1998; 248: 96-103
8. Kaneda Y, Ohmori T, Fujii A. The serotonin syndrome: investigation using the Japanese version of the Serotonin Syndrome Scale. Psychiatry Res 2001; 105: 135-142
9. Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf H-D, Wolf D. The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr Scand 1989; 80 (suppl 350): 91-92
10. Kudo K, Sasaki I, Tsuchiyama K, Akiyoshi J, Nagayama H, Fujii I. Serotonin syndrome during clomipramine monotherapy: comparison of two diagnostic criteria. Psychiatry Clin Neurosci 1997; 51: 43-46
11. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17: 208-221
12. Lejoyeux M, Adès J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment. CNS Drugs 1994; 2: 132-143
13. Lejoyeux M, Rouillon F, Adès J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine. Acta Psychiatr Scand 1993; 88: 369-371
14. Mills KC. Serotonin syndrome. Am Fam Physician 1995; 52: 1475-1482
15. Radomski JW, Dursun SM, Reveley MA. Toxic serotonin syndrome (ITS): an update and revised diagnostic criteria (abstract). J Psychopharmacol 1995; 9 (suppl 2): A21
16. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-713